Trials / Completed
CompletedNCT02550106
Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment
A Phase IV, Multicenter, Single-arm and Open-label Study With Omalizumab (Xolair®) in Chronic Spontaneous Urticaria (CSU) Patients Who Remain Symptomatic Despite Antihistamine (H1) Treatment
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 136 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the proportion of patients with an urticaria control test \[UCT\] score of greater than or equal to 12 at Week 12.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OMALIZUMAB | sub cutaneous injections of 300 mg every 4 weeks until Week 8. |
Timeline
- Start date
- 2015-04-22
- Primary completion
- 2016-01-11
- Completion
- 2016-01-11
- First posted
- 2015-09-15
- Last updated
- 2020-02-25
- Results posted
- 2020-02-25
Locations
29 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02550106. Inclusion in this directory is not an endorsement.